Castle Biosciences Inc

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Castle Biosciences posts robust Q4 earnings, eyes growth opportunities ahead

Castle Biosciences reported strong financial performance in Q4 and full-year 2022, driven by revenue growth and test volume increase.
The company's focus on expanding commercial teams, R&D initiatives, and new laboratory openings positions it for future growth.
Challenges lie in convincing commercial payers and maintaining gross margin, requiring strategic actions and evidence-based outcomes.
Opportunities exist in demonstrating patient outcomes, NCCN guideline inclusion, and leveraging cash reserves for growth.

Castle Biosciences reports robust Q1 performance and navigates growth challenges

Castle Biosciences delivered a strong Q1 2023 with notable revenue growth and volume increases, supported by a solid financial position.
The company's focus on dermatology, gastroenterology, and mental health segments, along with positive clinical study results, underpin its market strength.
While facing challenges in sales execution and territory management, Castle Biosciences is strategically positioned to capitalize on growth opportunities in its key product lines.

Castle Biosciences reports robust Q2 growth and navigates coverage challenges

Castle Biosciences delivered strong financial performance in Q2 2023, with revenue and test volume growth surpassing expectations.
Despite challenges in coverage and operational constraints, the company's strategic focus on test value and market expansion presents promising growth prospects.
With a solid financial position, ongoing efforts to address challenges, and capitalize on opportunities, Castle Biosciences is poised for continued success in the precision medicine market.

Castle Biosciences reports stellar Q3 results and eyes market expansion

Castle Biosciences delivered exceptional financial results, raised revenue guidance, and showcased strong growth across its test portfolio. The company's focus on innovation, clinical impact, and market recognition positions it well for future success. While challenges in managing growth and competition exist, Castle Biosciences has opportunities to capitalize on its strengths and expand its market presence.

Castle Biosciences reports stellar 2023 performance and eyes new markets

Castle Biosciences delivered strong financial performance in Q4 and full year 2023, driven by robust revenue growth and impressive test volume results across key tests.
The company showcased clinical efficacy, innovation, and financial discipline, while navigating challenges such as cost pressures and reimbursement uncertainties.
Strategic initiatives like expanding test portfolios, managing costs effectively, and exploring new growth avenues position Castle Biosciences for continued success and market leadership.
With a focus on maintaining profitability, investing in growth, and leveraging opportunities, Castle Biosciences is poised for sustained growth and value creation in the future.

Castle Biosciences excels in Q1 2024, eyes strategic growth opportunities

Castle Biosciences delivered exceptional financial and operational results in Q1 2024, showcasing strong revenue growth, improved margins, and product advancements. While facing some challenges with test volumes and Medicare coverage, the company's solid performance and market position present promising opportunities for future growth.

Castle Biosciences excels in Q2, raises guidance amid test volume surge

Castle Biosciences delivered outstanding financial results in Q2 2024, showcasing strong revenue growth, improved margins, and a significant net income turnaround.
The company's focus on innovation and clinical value in its tests positions it well for sustained growth and market leadership in precision diagnostics.
While facing challenges in maintaining growth momentum and operational efficiency, Castle Biosciences has opportunities to expand its market presence and drive international expansion.
Overall, Castle Biosciences' Q2 performance reflects a resilient and promising trajectory, underpinned by strategic strengths and a commitment to advancing patient care.

Castle Biosciences excels in Q3, poised for sustained growth

Castle Biosciences' Q3 performance reflects strong revenue growth, financial stability, and a positive outlook for future expansion.
The company's focus on product innovation, market penetration, and financial discipline positions it well for continued success.
While challenges exist in maintaining growth and profitability, Castle Biosciences has ample opportunities for further market expansion and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxSCC--Castle announced that it has received approval from the New York State Department of Health for its DecisionDx-SCC test.

Castle Biosciences Announces Receipt of New York Laboratory Permit

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BairdESGConference--Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the Baird 2021 Healthcare ESG Symposium on June 17, 2021, at 11:20 a.m. Eastern time. A live audio webcast of the company's presentation will be available by visiting Castle Biosciences' web

Castle Biosciences to Participate at the Baird 2021 Healthcare ESG Symposium

SAN DIEGO, May 26, 2021   /PRNewswire/ -- AltheaDx, a commercial stage, precision medicine company with the world's leading pharmacogenomics test for anxiety and depression announced today that it has appointed Derek Maetzold to its Board of Directors. Mr. Maetzold is AltheaDx's fourth Director and brings not only strong knowledge of the diagnostics industry, but also operations and management experience.

AltheaDx, Inc. appoints industry veteran Derek Maetzold to its Board of Directors

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #headquarters--Castle today announced it will host a ribbon cutting ceremony at its new corporate headquarters.

Castle Biosciences to Host Ribbon Cutting Ceremony at New Corporate Headquarters

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AmericanSkinAssociation--Castle today announced its collaboration with the American Skin Association to provide a 2021 research grant in the area of melanoma.

Castle Biosciences Supports the American Skin Association with Research Grant

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle today announced a publication describing the findings of a squamous cell carcinoma (SCC) gene expression profiling (GEP) expert panel.

Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #OpcoMedTech2021--Castle today announced that management will participate in the Oppenheimer MedTech, Tools, & Diagnostics Summit, May 26, 2021.

Castle Biosciences to Participate in the Oppenheimer MedTech, Tools, & Diagnostics Summit

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BoardofDirectors--Castle today announced that Tiffany Olson has been appointed to its board of directors, effective immediately.

Tiffany Olson, Seasoned Diagnostics Executive, Joins Castle Biosciences' Board of Directors

Castle Biosciences, Inc (CSTL) CEO Derek Maetzold on Q1 2021 Results - Earnings Call Transcript

Shares of Castle Biosciences (NASDAQ:CSTL) were unchanged in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 666.67% over the past year to ($0.17), which beat the estimate of ($0.24).

Castle Biosciences: Q1 Earnings Insights

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle today announced its financial results for the first quarter ended March 31, 2021.

Castle Biosciences Announces First Quarter 2021 Results

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #dermatologicdisease--Castle today announced its pipeline initiative to develop a genomic test aimed at predicting systemic therapy response.

Castle Biosciences Announces Pipeline Initiative to Develop Genomic Test Targeting Systemic Therapy Response in Patients with Psoriasis, Atopic Dermatitis and Related Conditions

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #GenomicTesting--Castle has been selected as the winner of the “Best New Technology Solution for Oncology.”

Castle Biosciences Recognized for Skin Cancer Diagnostics Innovation in 2021 MedTech Breakthrough Awards Program

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ARVO--Castle presented data on its 15-gene expression profile (15-GEP) test, DecisionDx®-UM, at ARVO 2021.

New Data Demonstrate that 99% of Surveyed Patients Diagnosed With Uveal Melanoma Gain Value From DecisionDx-UM Test

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Melanoma--Castle Collaborates with the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S.

Castle Biosciences Collaborates With the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S.

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AmericanAcademyofDermatology--Castle today announced its national sponsorship of the American Academy of Dermatology's (AAD) "Skin Cancer, Take a Hike!"

Castle Biosciences Supports American Academy of Dermatology's "Skin Cancer, Take a Hike!™" Steps Challenge for Skin Cancer Awareness Month

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DiffDxMelanoma--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced it has signed a definitive agreement to acquire all of the equity of Myriad myPath, LLC (Myriad myPath Laboratory), from Myriad Genetics. Myriad myPath Laboratory is a CLIA-certified laboratory in Salt Lake City, where the myPath Melanoma 23-gene expression profile (GEP) test was develope

Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will release its financial results for the first quarter 2021 and provide a pipeline update, after the close of market on May 10, 2021.

Castle Biosciences to Release First Quarter 2021 Financial Results, Provide Pipeline Update and Host Conference Call on Monday, May 10, 2021

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AADVMX2021--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, will present data at the American Academy of Dermatology's Virtual Meeting Experience, being held April 23 – 25, 2021. The Company has two poster presentations highlighting its DecisionDx®-Melanoma and DecisionDx®-SCC genomic tests. Data presentation information is as follows: DecisionDx®-Melanoma: The p

Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DNANurses--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced participation in the Dermatology Nurses' Association 2021 Annual Convention. Castle presented posters highlighting each of the company's three skin cancer gene expression profile (GEP) tests. Poster information is as follows: DecisionDx®-Melanoma: The poster is entitled, “31-gene expressi

Castle Biosciences Presents Data at the Dermatology Nurses' Association 2021 Annual Convention

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #10thWCM--Castle presented data on its three skin cancer gene expression profile tests at the 10th World Congress of Melanoma.

Castle Biosciences Presents Data at the 10th World Congress of Melanoma and 17th European Association of Dermato-Oncology Congress

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle presented new data on the integration of the DecisionDx®-Melanoma test with clinicopathologic features (i31-GEP).

Late-Breaking New Independent Validation Study of 1,674 Patients Demonstrates Castle Biosciences' i31-GEP Artificial Intelligence Algorithm Improves Precision of Sentinel Lymph Node Positivity Prediction in Cutaneous Melanoma

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced data from an independent, prospective study published in the American Journal of Surgery demonstrating DecisionDx®-Melanoma's utility for prediction of outcomes in patients with cutaneous melanoma. DecisionDx-Melanoma is Castle's gene expression profile test that uses an individual patien

Largest, Independent, Prospective Study Demonstrates Utility of DecisionDx®-Melanoma for Prediction of Outcomes in Patients With Cutaneous Melanoma Referred for Sentinel Node Biopsy

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Melanoma--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of prospective, multi-center long-term outcomes data in cutaneous melanoma as impacted by DecisionDx®-Melanoma. DecisionDx-Melanoma is Castle's gene expression profile test that uses an individual patient's tumor biology to predict risk of cutaneous melanoma metastasis or

Castle Biosciences Announces Prospective, Multi-Center Publication Demonstrating DecisionDx®-Melanoma as Significant, Independent Predictor of Patient Outcomes in Cutaneous Melanoma

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announced it will collaborate with the Melanoma Research Foundation (MRF) to present “Ask the Expert” Managing Melanoma, a webinar series.

News for Castle Biosciences Inc Stock (CSTL)